转化生长因子-β（TGF-β）下调神经胶质瘤患者 NK 细胞和 CD8+T 细胞上的激活受体 NKG2D。
TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients.
机构信息
Department of Neurological Surgery, University of California-San Francisco, San Francisco, California 94143, USA.
出版信息
Neuro Oncol. 2010 Jan;12(1):7-13. doi: 10.1093/neuonc/nop009. Epub 2009 Nov 5.
Abstract
The activating receptor NKG2D, expressed by natural killer (NK) cells and CD8(+) T cells, has a role in the specific killing of transformed cells. We examined NKG2D expression in patients with glioblastoma multiforme and found that NKG2D was downregulated on NK cells and CD8(+) T cells. Expression of NKG2D on lymphocytes significantly increased following tumor resection and correlated with an increased ability to kill NKG2D ligand-positive tumor targets. Despite the presence of soluble NKG2D ligands in the sera of glioblastoma patients, NKG2D downregulation was primarily caused by tumor-derived tumor growth factor-beta, suggesting that blocking of this cytokine may have therapeutic benefit.
摘要
激活受体 NKG2D 表达于自然杀伤 (NK) 细胞和 CD8(+)T 细胞，在特异性杀伤转化细胞中发挥作用。我们检测了多形性胶质母细胞瘤患者的 NKG2D 表达情况，发现 NK 细胞和 CD8(+)T 细胞上的 NKG2D 表达下调。肿瘤切除后，淋巴细胞上的 NKG2D 表达显著增加，并与杀伤 NKG2D 配体阳性肿瘤靶细胞的能力增强相关。尽管胶质母细胞瘤患者的血清中存在可溶性 NKG2D 配体，但 NKG2D 的下调主要是由肿瘤衍生的肿瘤生长因子-β引起的，提示阻断这种细胞因子可能具有治疗益处。
相似文献
1
TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients.转化生长因子-β（TGF-β）下调神经胶质瘤患者 NK 细胞和 CD8+T 细胞上的激活受体 NKG2D。
Neuro Oncol. 2010 Jan;12(1):7-13. doi: 10.1093/neuonc/nop009. Epub 2009 Nov 5.
2
Reduced immune effector cell NKG2D expression and increased levels of soluble NKG2D ligands in multiple myeloma may not be causally linked.多发性骨髓瘤中免疫效应细胞 NKG2D 表达减少和可溶性 NKG2D 配体水平升高可能没有因果关系。
Cancer Immunol Immunother. 2010 Jun;59(6):829-39. doi: 10.1007/s00262-009-0807-3. Epub 2009 Dec 19.
3
Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.干扰素-γ下调NKG2D配体的表达，并损害自然杀伤细胞对MHC I类缺陷型黑色素瘤的NKG2D介导的细胞溶解作用。
Int J Cancer. 2009 Apr 1;124(7):1594-604. doi: 10.1002/ijc.24098.
4
Aberrantly decreased levels of NKG2D expression in children with kawasaki disease.川崎病患儿 NKG2D 表达水平异常降低。
Scand J Immunol. 2013 May;77(5):389-97. doi: 10.1111/sji.12022.
5
Prostate tumor-derived exosomes down-regulate NKG2D expression on natural killer cells and CD8+ T cells: mechanism of immune evasion.前列腺肿瘤来源的外泌体下调自然杀伤细胞和CD8 + T细胞上NKG2D的表达：免疫逃逸机制
PLoS One. 2014 Sep 30;9(9):e108925. doi: 10.1371/journal.pone.0108925. eCollection 2014.
6
TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells.转化生长因子-β和金属蛋白酶对恶性胶质瘤细胞表面NKG2D配体的表达有不同程度的抑制作用。
Brain. 2006 Sep;129(Pt 9):2416-25. doi: 10.1093/brain/awl205. Epub 2006 Aug 3.
7
RNA interference targeting transforming growth factor-beta enhances NKG2D-mediated antiglioma immune response, inhibits glioma cell migration and invasiveness, and abrogates tumorigenicity in vivo.靶向转化生长因子-β的RNA干扰增强NKG2D介导的抗胶质瘤免疫反应，抑制胶质瘤细胞迁移和侵袭，并消除体内致瘤性。
Cancer Res. 2004 Oct 15;64(20):7596-603. doi: 10.1158/0008-5472.CAN-04-1627.
8
Human tumor-derived exosomes down-modulate NKG2D expression.人肿瘤来源的外泌体下调NKG2D表达。
J Immunol. 2008 Jun 1;180(11):7249-58. doi: 10.4049/jimmunol.180.11.7249.
9
Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.可溶性 NKG2D 受体配体在 HIV-1 感染过程中释放，并损害 NK 细胞的 NKG2D 表达和细胞毒性。
FASEB J. 2013 Jun;27(6):2440-50. doi: 10.1096/fj.12-223057. Epub 2013 Feb 8.
10
Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients.转化生长因子β1分泌升高和自然杀伤细胞2D（NKG2D）下调是癌症患者自然杀伤细胞（NK）细胞毒性受损的基础。
J Immunol. 2004 Jun 15;172(12):7335-40. doi: 10.4049/jimmunol.172.12.7335.
引用本文的文献
1
CAR Cell-Derived Exosomes in Cancer Therapy: Biogenesis, Engineering Strategies and Antitumor Mechanisms.嵌合抗原受体（CAR）细胞衍生外泌体在癌症治疗中的作用：生物发生、工程策略及抗肿瘤机制
Int J Mol Sci. 2025 Aug 15;26(16):7890. doi: 10.3390/ijms26167890.
2
Proteins of the cancer cell secretome induce the protumoral microenvironment of diffuse intrinsic pontine glioma.癌细胞分泌组的蛋白质诱导弥漫性内在脑桥胶质瘤的促肿瘤微环境。
Neurooncol Adv. 2025 Jun 19;7(1):vdaf132. doi: 10.1093/noajnl/vdaf132. eCollection 2025 Jan-Dec.
3
Dissecting the Immunological Microenvironment of Glioma Based on IDH Status: Implications for Immunotherapy.基于异柠檬酸脱氢酶（IDH）状态剖析胶质瘤的免疫微环境：对免疫治疗的启示
Cells. 2025 Jul 7;14(13):1035. doi: 10.3390/cells14131035.
4
Recent advances and challenges of cellular immunotherapies in lung cancer treatment.细胞免疫疗法在肺癌治疗中的最新进展与挑战
Exp Hematol Oncol. 2025 Jul 7;14(1):94. doi: 10.1186/s40164-025-00679-8.
5
Interplay Between the Epigenome, the Microenvironment, and the Immune System in Neuroblastoma.神经母细胞瘤中表观基因组、微环境与免疫系统之间的相互作用
Cancers (Basel). 2025 May 29;17(11):1812. doi: 10.3390/cancers17111812.
6
Tumor-derived vesicles in immune modulation: focus on signaling pathways.肿瘤衍生囊泡在免疫调节中的作用：聚焦信号通路
Front Immunol. 2025 May 15;16:1581964. doi: 10.3389/fimmu.2025.1581964. eCollection 2025.
7
Reduced HLA-I Transcript Levels and Increased Abundance of a CD56 NK Cell Signature Are Associated with Improved Survival in Lower-Grade Gliomas.HLA-I转录水平降低及CD56自然杀伤细胞特征丰度增加与低级别胶质瘤患者生存率提高相关。
Cancers (Basel). 2025 May 5;17(9):1570. doi: 10.3390/cancers17091570.
8
AHR Agonist ITE Boosted PD1 Antibody's Effects by Inhibiting Myeloid-Derived Cells Suppressive Cells in an Orthotopic Mouse Glioma Model.在原位小鼠胶质瘤模型中，芳烃受体激动剂ITE通过抑制髓系来源的抑制性细胞增强了PD1抗体的效果。
Pharmaceuticals (Basel). 2025 Mar 27;18(4):471. doi: 10.3390/ph18040471.
9
Reactive Astrocytes in Glioma: Emerging Opportunities and Challenges.胶质瘤中的反应性星形胶质细胞：新出现的机遇与挑战
Int J Mol Sci. 2025 Mar 23;26(7):2907. doi: 10.3390/ijms26072907.
10
Breast Cancer and Tumor Microenvironment: The Crucial Role of Immune Cells.乳腺癌与肿瘤微环境：免疫细胞的关键作用
Curr Oncol. 2025 Feb 28;32(3):143. doi: 10.3390/curroncol32030143.
本文引用的文献
1
2
A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells.一种新型的信号转导和转录激活因子3激活抑制剂对已形成的中枢神经系统黑色素瘤有效，并能抑制调节性T细胞。
Clin Cancer Res. 2008 Sep 15;14(18):5759-68. doi: 10.1158/1078-0432.CCR-08-0377.
3
Incidence and prognostic impact of FoxP3+ regulatory T cells in human gliomas.FoxP3+调节性T细胞在人类胶质瘤中的发生率及预后影响
Clin Cancer Res. 2008 Aug 15;14(16):5166-72. doi: 10.1158/1078-0432.CCR-08-0320.
4
Malignancy after kidney transplantation: results of 400 patients from a single center.肾移植后恶性肿瘤：来自单一中心的400例患者的结果
Clin Transplant. 2008 Jul-Aug;22(4):424-7. doi: 10.1111/j.1399-0012.2008.00802.x. Epub 2008 Feb 27.
5
Acute upregulation of an NKG2D ligand promotes rapid reorganization of a local immune compartment with pleiotropic effects on carcinogenesis.NKG2D配体的急性上调促进局部免疫区室的快速重组，对肿瘤发生具有多效性作用。
Nat Immunol. 2008 Feb;9(2):146-54. doi: 10.1038/ni1556. Epub 2008 Jan 6.
6
Cytotoxic T-lymphocyte-associated antigen-4.细胞毒性T淋巴细胞相关抗原4
Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5238-42. doi: 10.1158/1078-0432.CCR-07-0813.
7
The combined actions of NK and T lymphocytes are necessary to reject an EGFP+ mesenchymal tumor through mechanisms dependent on NKG2D and IFN gamma.自然杀伤细胞（NK）和T淋巴细胞的联合作用对于通过依赖自然杀伤细胞2D（NKG2D）和γ干扰素的机制排斥增强绿色荧光蛋白（EGFP）阳性间充质肿瘤是必要的。
Int J Cancer. 2007 Sep 15;121(6):1282-95. doi: 10.1002/ijc.22795.
8
Reduced natural killer (NK) function associated with high-risk myelodysplastic syndrome (MDS) and reduced expression of activating NK receptors.与高危骨髓增生异常综合征（MDS）相关的自然杀伤（NK）功能降低以及活化NK受体表达减少。
Blood. 2007 Jun 1;109(11):4816-24. doi: 10.1182/blood-2006-07-035519. Epub 2007 Mar 6.
9
Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors.白细胞介素-15可挽救耐受性CD8+ T细胞，用于已建立肿瘤的过继性免疫治疗。
Nat Med. 2006 Mar;12(3):335-41. doi: 10.1038/nm1359. Epub 2006 Feb 12.
10
Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance.激活型NKG2D受体配体的持续局部表达会损害体内的自然细胞毒性并降低肿瘤免疫监视。
Nat Immunol. 2005 Sep;6(9):928-37. doi: 10.1038/ni1239. Epub 2005 Aug 14.
Zotero 插件